Avion Pharmaceuticals & Albion Labs v. Lupin — Dismissed Without Prejudice After 580 Days
Avion Pharmaceuticals and Albion Laboratories sued Lupin Limited and Lupin Pharmaceuticals in Delaware over US7838042B2, a patent covering Levonorgestrel/Ethinyl Estradiol tablets combined with ferrous bisglycinate iron supplementation. The parties stipulated to dismissal without prejudice after nearly 16 months, with each side bearing its own costs.
Stipulated exit in a specialty pharma contraceptive-iron patent dispute
On June 2, 2022, Avion Pharmaceuticals, LLC and Albion Laboratories, Inc. filed suit against Lupin Limited and Lupin Pharmaceuticals, Inc. in the Delaware District Court under Case No. 1:22-cv-00729, presided over by Judge Christopher J. Burke. The action asserted infringement of US7838042B2, which covers oral contraceptive tablet formulations combining levonorgestrel, ethinyl estradiol, and ferrous bisglycinate — a chelated iron form associated with improved gastrointestinal tolerability.
The case closed on January 3, 2024, via a stipulated dismissal filed under Federal Rules of Civil Procedure 41(a)(1) and 41(c). Critically, the dismissal was entered without prejudice, meaning plaintiffs Avion and Albion explicitly preserved their right to bring the same infringement claims against Lupin in a future action. All parties agreed to absorb their own legal costs, disbursements, and attorneys’ fees, with no financial award in either direction.
At 580 days, the case resolved well before any trial date, suggesting the parties may have reached an accommodation — whether commercial, licensing, or otherwise — that is not reflected in the public record. The without-prejudice structure is notable: it leaves the litigation door open, which may indicate ongoing negotiations or a settlement with contingent terms. The public record does not disclose any licensing agreement, product withdrawal, or ANDA-related settlement terms.
Filing to voluntary dismissal in 580 days
580 days — case resolved before trial, consistent with early negotiated exit
Stipulated dismissal without prejudice — what the terms mean for each party
Rules 41(a)(1) and 41(c): Stipulated dismissal explained
A dismissal under FRCP 41(a)(1) is filed by the parties jointly and does not require court approval, making it the fastest and cleanest exit route in federal civil litigation. Rule 41(c) extends this mechanism to counterclaims and defenses. Here, both Lupin’s affirmative defenses and any counterclaims it had asserted are also extinguished — but only temporarily, given the without-prejudice qualifier.
Joint stipulation — no court order requiredWithout prejudice: the litigation door remains open
Dismissal without prejudice means Avion and Albion are legally free to refile the same patent infringement claims against Lupin. This is materially different from a with-prejudice dismissal, which would permanently bar re-litigation of those claims. The without-prejudice structure here is consistent with parties who have reached a contingent agreement or are still in active commercial discussions, but the public record does not confirm any such arrangement.
Plaintiffs may refile — claims not extinguishedEach side bears its own costs — no winner declared
The stipulation explicitly states that all parties shall bear their own costs, disbursements, and attorneys’ fees. In U.S. patent litigation, fee awards under 35 U.S.C. § 285 require an ‘exceptional case’ finding — rare and contested. An own-costs resolution avoids that fight entirely and is typical of negotiated exits where neither side wishes to signal weakness or concession. It provides no signal about the underlying merits of the infringement claim.
No fee-shifting — neutral cost outcomeGeneric drug pathway: the Hatch-Waxman backdrop
This dispute is characteristic of Hatch-Waxman litigation, in which a branded or specialty pharma patent holder sues a generic manufacturer following an ANDA filing with a Paragraph IV certification. The product at issue — a levonorgestrel/ethinyl estradiol tablet with ferrous bisglycinate — suggests Lupin sought to market a generic version. Dismissal without prejudice in ANDA cases often reflects a negotiated market entry date or licensing arrangement, though neither is confirmed in the public record here.
Likely Hatch-Waxman / ANDA contextFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Avion Pharmaceuticals, LLC | Company | Specialty pharma and nutraceutical companies — co-holders of US7838042B2Search in Eureka ↗ |
| Defendant | Lupin Limited | Company | Lupin Limited and U.S. subsidiary Lupin Pharmaceuticals — major generic drug manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Andrew T. Dufrense , PH.D. | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Autumn N. Nero | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Brandon M. White | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Jonathan I Tietz | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael A. Chajon | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Olivia Radics | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Richard Charles Weinblatt | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Stamatios Stamoulis | Attorney | Counsel for Avion Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Corinne S. Hockman | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Daniel P. Withers | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Jieun Lee | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Kurt A. Mathas | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Merritt Westcott | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Michael A. Meneghini | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Michael K. Nutter | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Christopher J. Burke | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulated dismissal under FRCP 41(a)(1) and 41(c) is a bilateral, court-filing-free exit that terminates all claims and defenses between the parties — but only on a without-prejudice basis. The explicit inclusion of Rule 41(c) is significant: it ensures Lupin’s counterclaims and invalidity defenses are also dismissed, resetting the litigation slate. The own-costs clause forecloses any post-dismissal fee motion. Taken together, the order leaves the legal relationship between these parties entirely unresolved on the merits.
US7838042B2 — Oral contraceptive tablet with chelated iron supplementation
US7838042B2, filed under application number US10/828827, covers a pharmaceutical formulation combining levonorgestrel and ethinyl estradiol — the active hormonal agents in a class of oral contraceptives — with ferrous bisglycinate, a chelated iron compound. The chelation to the amino acid glycine is understood to improve iron bioavailability and reduce gastrointestinal side effects compared to inorganic iron salts, a clinically meaningful differentiation point in combination products targeting iron-deficient populations.
The commercial significance of this patent lies at the intersection of women’s health pharmaceuticals and specialty mineral supplementation — a combination product category where generic entry creates meaningful revenue risk for branded holders. Albion Laboratories, as co-plaintiff, is a recognised innovator in amino acid-chelated mineral technology, suggesting the patent family may extend beyond this single grant. Any generic or biosimilar developer targeting this product space should treat this patent as a live enforcement risk, particularly given the without-prejudice dismissal.
Should your formulation team run an FTO against US7838042B2?
Any R&D or regulatory team developing an oral contraceptive product that includes a chelated iron component — particularly ferrous bisglycinate — should assess their exposure to US7838042B2 before advancing an ANDA or NDA filing. The patent’s claims likely extend to the formulation combination itself, not merely the manufacturing process, which means product-level FTO analysis is essential. Given the active enforcement history, this is not a patent to assume is commercially non-asserted.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US7838042B2 against your formulation parameters, identify continuation and divisional patents in the Albion/Avion family, and flag any third-party design-around literature. Claim monitoring alerts can notify your team if new related applications publish — a critical early-warning function in a space where enforcement has already been demonstrated.
Run a freedom-to-operate analysis on US7838042B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman patent disputes in oral contraceptive and iron formulation tech
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the specialty pharma patent IP landscape
A without-prejudice dismissal in an ANDA-adjacent dispute suggests unresolved commercial dynamics that IP teams in generic pharma should monitor closely.
Without-prejudice exits in ANDA cases rarely signal permanent peace
When ANDA-linked patent disputes settle without prejudice, the underlying commercial tension — over generic market entry timing — typically persists. Lupin retains its product development position, but Avion and Albion retain full re-litigation rights. IP teams at generics firms should treat such exits as pauses, not conclusions, and maintain freedom-to-operate readiness on US7838042B2.
Ferrous bisglycinate formulation patents are an active enforcement zone
The combination of hormonal contraceptives with chelated iron forms like ferrous bisglycinate represents a niche but litigated formulation space. Patent holders in this area — including Albion Laboratories, a specialist in amino acid-chelated mineral technology — have both the IP assets and commercial incentive to enforce against generics. Companies developing similar formulations should audit their ANDA filings against this patent family.
Avion v Lupin — key questions answered
The case was dismissed without prejudice on January 3, 2024, via a joint stipulation under FRCP 41(a)(1) and 41(c). Avion Pharmaceuticals and Albion Laboratories had sued Lupin Limited and Lupin Pharmaceuticals over US7838042B2, covering a levonorgestrel/ethinyl estradiol tablet with ferrous bisglycinate. All parties agreed to bear their own costs. No merits ruling was issued.
Dismissed without prejudice means Avion Pharmaceuticals and Albion Laboratories retain the legal right to refile the same patent infringement claims against Lupin in the future. It is not a final resolution on the merits. This contrasts with a with-prejudice dismissal, which would permanently bar re-litigation of the same claims. The dismissal does not confirm infringement or invalidity of US7838042B2.
The product at issue is a tablet formulation combining Levonorgestrel, Ethinyl Estradiol, and Ferrous Bisglycinate. This is consistent with a Hatch-Waxman dispute in which a generic manufacturer — here Lupin — sought to market a generic equivalent of a branded oral contraceptive product that also delivers chelated iron supplementation.
US7838042B2 is a U.S. patent covering a pharmaceutical formulation of levonorgestrel, ethinyl estradiol, and ferrous bisglycinate. Based on the case record, it is associated with Avion Pharmaceuticals LLC and Albion Laboratories Inc., who jointly asserted it as co-plaintiffs. Albion Laboratories is known for amino acid-chelated mineral technology, which underlies the ferrous bisglycinate component of the claimed formulation.
Delaware is a common venue for Hatch-Waxman patent litigation because many pharmaceutical companies — including Lupin Pharmaceuticals Inc. — are incorporated there, making venue straightforward to establish. Delaware District Court also has an experienced bench in pharmaceutical patent matters, making it a preferred jurisdiction for plaintiffs asserting drug formulation patents against generic manufacturers.
PatSnap Eureka searches patents and litigation data to answer instantly.